2026 Q1 -tulosraportti
59 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,52%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sittenChat GPT is strongly biased for LLY, which is not surprising, as it operates with consensus. One finds all the optimistic and likewise pessimistic arguments for the two companies. But if you press it for numbers and ask it to relate to them, the message is suddenly different!? Try to see what it writes here: To calculate the percentage difference (how much larger the capital inflow is compared to the outflow), we take the difference between the two figures and measure it against the outflow.The calculation result shows an extremely significant difference, which in black and white confirms your thesis about the massive accumulation in Novo Nordisk:Novo Nordisk (NVO): The inflow is 75.60 % greater than the outflow.Eli Lilly (LLY): The inflow is merely 4.57 % greater than the outflow.What the numbers tell about trading activityWhen we compare the two percentages, the institutional behavior becomes very clear:Aggressive accumulation in Novo Nordisk: For every dollar withdrawn from the Novo stock, almost 1.76 dollars flow into it. Funds aggressively absorb the available shares in the market, which is the classic sign of an intensified accumulation phase, while the price is low.Close to equilibrium (Distribution) in Eli Lilly: Although the total volumes in Lilly are enormous, the balance between buying and selling is almost 1:1 (only 4.57 % difference). This means that an enormous volume of trading (churn) is taking place, where large positions change hands rapidly. Institutional investors are effectively just covering each other's trades and distributing large blocks of shares to new buyers, while the price is at its peak.
Actually, the conclusion on Novo I have mentioned before, the difference between short-term and long-term investor approach.
·2 t sittenA significant part of the mentioned problems is also seen with Rybelsus, which is the Danish version of the Wegovy pill. See promedicin.dk/Rybelsus
It is diabetes medicine, which contains the same active ingredient but you cannot say that it is the same. For example, graphite and diamonds both consist of carbon, but are far from the same, without comparison otherwise...
·4 t sitten · MuokattuI guess Foundayo will soon be taken off the market due to serious side effects (which Lilly strongly warns against on the website, pop-up warning on the front page) and the lack of sales. That must simply damage Lilly's reputation too much and the scandals on could be on the way. Novo back at price 500-650Yes, that is indeed a warning that cannot be ignored, and Wegovy doesn't have those, so yes, interesting if they have to wait for their next pill 👌😬- ·5 t sittenSerious warning on Eli's own page: https://foundayo.lilly.com/
- ·18 t sittenFoundayo Day 3 on 0.8mg and omg last night was intense with stomach sickness and bowel problems. I definitely didn't want to eat. Today it felt better until around 4 PM then all the stomach discomfort and everything came back again. Any suggestions ??? Anyone taking Imodium or Zofran or anything else for their symptoms? I take my medicine at 8:30 AM before I eat
That's hardly facts. It's an observation from a person. That person could just as well have eaten some bad food based on that story.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
59 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,52%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenChat GPT is strongly biased for LLY, which is not surprising, as it operates with consensus. One finds all the optimistic and likewise pessimistic arguments for the two companies. But if you press it for numbers and ask it to relate to them, the message is suddenly different!? Try to see what it writes here: To calculate the percentage difference (how much larger the capital inflow is compared to the outflow), we take the difference between the two figures and measure it against the outflow.The calculation result shows an extremely significant difference, which in black and white confirms your thesis about the massive accumulation in Novo Nordisk:Novo Nordisk (NVO): The inflow is 75.60 % greater than the outflow.Eli Lilly (LLY): The inflow is merely 4.57 % greater than the outflow.What the numbers tell about trading activityWhen we compare the two percentages, the institutional behavior becomes very clear:Aggressive accumulation in Novo Nordisk: For every dollar withdrawn from the Novo stock, almost 1.76 dollars flow into it. Funds aggressively absorb the available shares in the market, which is the classic sign of an intensified accumulation phase, while the price is low.Close to equilibrium (Distribution) in Eli Lilly: Although the total volumes in Lilly are enormous, the balance between buying and selling is almost 1:1 (only 4.57 % difference). This means that an enormous volume of trading (churn) is taking place, where large positions change hands rapidly. Institutional investors are effectively just covering each other's trades and distributing large blocks of shares to new buyers, while the price is at its peak.Actually, the conclusion on Novo I have mentioned before, the difference between short-term and long-term investor approach.
- ·2 t sittenA significant part of the mentioned problems is also seen with Rybelsus, which is the Danish version of the Wegovy pill. See promedicin.dk/RybelsusIt is diabetes medicine, which contains the same active ingredient but you cannot say that it is the same. For example, graphite and diamonds both consist of carbon, but are far from the same, without comparison otherwise...
- ·4 t sitten · MuokattuI guess Foundayo will soon be taken off the market due to serious side effects (which Lilly strongly warns against on the website, pop-up warning on the front page) and the lack of sales. That must simply damage Lilly's reputation too much and the scandals on could be on the way. Novo back at price 500-650Yes, that is indeed a warning that cannot be ignored, and Wegovy doesn't have those, so yes, interesting if they have to wait for their next pill 👌😬
- ·5 t sittenSerious warning on Eli's own page: https://foundayo.lilly.com/
- ·18 t sittenFoundayo Day 3 on 0.8mg and omg last night was intense with stomach sickness and bowel problems. I definitely didn't want to eat. Today it felt better until around 4 PM then all the stomach discomfort and everything came back again. Any suggestions ??? Anyone taking Imodium or Zofran or anything else for their symptoms? I take my medicine at 8:30 AM before I eatThat's hardly facts. It's an observation from a person. That person could just as well have eaten some bad food based on that story.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
2026 Q1 -tulosraportti
59 päivää sitten
‧1 t 2 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
7,95 DKK/osake
Viimeisin osinko
3,52%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenChat GPT is strongly biased for LLY, which is not surprising, as it operates with consensus. One finds all the optimistic and likewise pessimistic arguments for the two companies. But if you press it for numbers and ask it to relate to them, the message is suddenly different!? Try to see what it writes here: To calculate the percentage difference (how much larger the capital inflow is compared to the outflow), we take the difference between the two figures and measure it against the outflow.The calculation result shows an extremely significant difference, which in black and white confirms your thesis about the massive accumulation in Novo Nordisk:Novo Nordisk (NVO): The inflow is 75.60 % greater than the outflow.Eli Lilly (LLY): The inflow is merely 4.57 % greater than the outflow.What the numbers tell about trading activityWhen we compare the two percentages, the institutional behavior becomes very clear:Aggressive accumulation in Novo Nordisk: For every dollar withdrawn from the Novo stock, almost 1.76 dollars flow into it. Funds aggressively absorb the available shares in the market, which is the classic sign of an intensified accumulation phase, while the price is low.Close to equilibrium (Distribution) in Eli Lilly: Although the total volumes in Lilly are enormous, the balance between buying and selling is almost 1:1 (only 4.57 % difference). This means that an enormous volume of trading (churn) is taking place, where large positions change hands rapidly. Institutional investors are effectively just covering each other's trades and distributing large blocks of shares to new buyers, while the price is at its peak.Actually, the conclusion on Novo I have mentioned before, the difference between short-term and long-term investor approach.
- ·2 t sittenA significant part of the mentioned problems is also seen with Rybelsus, which is the Danish version of the Wegovy pill. See promedicin.dk/RybelsusIt is diabetes medicine, which contains the same active ingredient but you cannot say that it is the same. For example, graphite and diamonds both consist of carbon, but are far from the same, without comparison otherwise...
- ·4 t sitten · MuokattuI guess Foundayo will soon be taken off the market due to serious side effects (which Lilly strongly warns against on the website, pop-up warning on the front page) and the lack of sales. That must simply damage Lilly's reputation too much and the scandals on could be on the way. Novo back at price 500-650Yes, that is indeed a warning that cannot be ignored, and Wegovy doesn't have those, so yes, interesting if they have to wait for their next pill 👌😬
- ·5 t sittenSerious warning on Eli's own page: https://foundayo.lilly.com/
- ·18 t sittenFoundayo Day 3 on 0.8mg and omg last night was intense with stomach sickness and bowel problems. I definitely didn't want to eat. Today it felt better until around 4 PM then all the stomach discomfort and everything came back again. Any suggestions ??? Anyone taking Imodium or Zofran or anything else for their symptoms? I take my medicine at 8:30 AM before I eatThat's hardly facts. It's an observation from a person. That person could just as well have eaten some bad food based on that story.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt